Novel Compounds to Treat Canine Histiocytic Sarcomas and Other Malignancies
Histiocytic sarcomas are very aggressive and invasive tumors that occur with high incidence in Bernese Mountain dogs, Rottweilers, Flat Coated Retrievers, and Golden Retrievers. The prognosis of histiocytic sarcomas is poor with median survival time of a few weeks to a few months. The currently available clinical treatments, including some proteasome inhibitors, are unsuitable for canine patients due to high cost and high toxicity. MSU researchers have developed novel compounds that can inhibit proteasome activity and suppress the proliferation of canine histiocytic sarcoma (HS) cell lines. These compounds can be used as a novel cancer treatment, which gives new hope for the development of an effective treatment for a variety of both canine and human cancers.
Description of Technology
The MSU research team has developed promising novel proteasome inhibitors that can be used to treat canine histiocytic sarcoma. These small molecules were found to be effective in suppressing the proliferation of canine HS cell lines, as well as other cancer cell lines like lymphoma, osteosarcoma in both canines and humans. Since the preliminary efficacy and toxicity tests also showed promising results, the objective of the team is to conduct clinical trials and develop these compounds into clinically relevant treatment for canine histiocytic sarcoma.
- Improvement over current treatments: The compounds target an alternative mechanism to inhibit proteasome activity, serving as an alternate treatment to proteasome inhibitors currently available in the market.
- Low toxicity alternative with high efficacy: The traditional proteasome inhibitors are highly toxic and often lose effectiveness when patients develop resistance. These small molecules developed by the MSU team have shown promising results in preliminary efficacy and toxicity tests.
- Orally bioavailable
- Anti-cancer treatment
- Research compound
- Canine and feline histiocytic sarcoma treatment
- Potential use in other cancer treatments
Licensing Rights Available
Full licensing rights available
Inventors: Dr. Vilma Yuzbasiyan-Gurkan, Dr. Jetze Tepe
For Information, Contact:
Michigan State University